• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Stryker Corporation

    9/4/24 4:13:52 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care
    Get the next $SYK alert in real time by email
    FWP 1 d131058dfwp.htm FWP FWP
        

    Filed Pursuant to Rule 433

    Registration Statement No. 333-275853

    September 4, 2024

    Final Term Sheet

     

    LOGO

    €800,000,000 3.375% Notes due 2032

    €600,000,000 3.625% Notes due 2036

     

    Issuer:

      

    Stryker Corporation

     

       

    2032 Notes

     

    2036 Notes

    Security Type:   3.375% Notes due 2032   3.625% Notes due 2036
    Principal Amount:   €800,000,000   €600,000,000
    Maturity Date:   September 11, 2032   September 11, 2036
    Interest Payment Dates:   Each September 11, commencing September 11, 2025  

    Each September 11, commencing

    September 11, 2025

    Day Count Convention:   Actual/Actual (ICMA)   Actual/Actual (ICMA)
    Coupon (Interest Rate):   3.375% per annum   3.625% per annum
    Benchmark German Government Security:   DBR 1.700% due August 15, 2032   DBR 0.000% due May 15, 2036
    Benchmark German Government Security Price/Yield:   €97.10; 2.100%   €76.56; 2.312%
    Spread to Benchmark German Government Security:   +132.4 bps   +141.7 bps
    Yield to Maturity:   3.424%   3.729%
    Mid-Swap Yield:   2.424%   2.499%
    Spread to Mid-Swap Yield:   +100 bps   +123 bps
    Price to Public:   99.662%   99.008%


    Optional Redemption Provisions:

       

    Make-Whole Call:

      Prior to June 11, 2032, Comparable Government Bond Rate + 20 bps  

    Prior to June 11, 2036, Comparable

    Government Bond Rate + 25 bps

    Par Call:

      On or after June 11, 2032, at par   On or after June 11, 2036, at par
    ISIN:   XS2892944732   XS2892944815
    Common Code:   289294473   289294481

     

    Expected Ratings* (Moody’s/S&P):    Baa1/BBB+
    Trade Date:    September 4, 2024
    Settlement Date**:    September 11, 2024 (T+5)
    Joint Book-Running Managers:   

    Citigroup Global Markets Limited

    Goldman Sachs & Co. LLC

    Barclays Bank PLC

    BNP Paribas
    Merrill Lynch International

    Senior Co-Managers:   

    Deutsche Bank AG, London Branch

    HSBC Bank plc

    MUFG Securities EMEA plc

     

    *

    Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.

    **

    It is expected that delivery of the notes will be made against payment therefor on or about September 11, 2024, which is the fifth U.S. business day following the date of the pricing of the notes. Under Rule 15c6-1 under the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day unless the parties to that trade expressly agree otherwise. Accordingly, purchasers of the notes who wish to trade the notes prior to the first business day preceding the settlement date will be required, by virtue of the fact that the notes initially will settle in T+5, to specify an alternative settlement cycle at the time of any such trade to prevent failed settlement and should consult their own advisors.

    UK MiFIR – professionals/ECPs-only /No PRIIPs or UK PRIIPs KID – Manufacturer target market (UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs or UK PRIIPs key information document (KID) has been prepared as not available to retail in the European Economic Area (the “EEA”) or UK.


    In member states of EEA, this communication is only addressed to, and directed at, a limited number of persons who are “qualified investors” (“EEA Qualified Investors”) within the meaning of Regulation (EU) 2017/1129, as amended. This communication must not be acted on or relied on, in any member state of the EEA, by persons who are not EEA Qualified Investors.

    The communication of this term sheet and any other document or materials relating to the issue of the notes is not being made, and such documents and/or materials have not been approved, by an authorized person for the purposes of section 21 of the United Kingdom’s Financial Services and Markets Act 2000, as amended. Accordingly, this term sheet and such other documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. This term sheet and such other documents and/or materials are for distribution only to persons who (i) have professional experience in matters relating to investments and who fall within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Financial Promotion Order”)), (ii) fall within Article 49(2)(a) to (d) of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are other persons to whom it may otherwise lawfully be made under the Financial Promotion Order (all such persons together being referred to as “relevant persons”). This term sheet and such other documents and/or materials are directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this term sheet and any other document or materials relates will be engaged in only with relevant persons. Any person in the United Kingdom that is not a relevant person should not act or rely on this term sheet or any other documents and/or materials relating to the issue of the notes or any of their contents.

    The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Citigroup Global Markets Limited toll-free at 1-800-831-9146, Goldman Sachs & Co. LLC toll-free at 1-866-471-2526, Barclays Bank PLC toll-free at 1-888-603-5847, BNP Paribas toll-free at 1-800-854-5674 or Merrill Lynch International toll-free at 1-800-294-1322.

    Get the next $SYK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SYK

    DatePrice TargetRatingAnalyst
    9/18/2025$420.00Neutral
    Rothschild & Co Redburn
    2/26/2025$450.00Buy
    Citigroup
    12/2/2024$370.00 → $445.00Equal-Weight → Overweight
    Morgan Stanley
    9/10/2024$405.00Outperform
    Wolfe Research
    5/30/2024$372.00Neutral
    Goldman
    5/22/2024$392.00Hold → Buy
    Needham
    1/31/2024$315.00 → $360.00Hold → Buy
    Canaccord Genuity
    10/20/2023$345.00Buy
    ROTH MKM
    More analyst ratings

    $SYK
    SEC Filings

    View All

    Stryker Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - STRYKER CORP (0000310764) (Filer)

    12/4/25 4:16:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Stryker Corporation

    144 - STRYKER CORP (0000310764) (Subject)

    11/14/25 4:27:05 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Stryker Corporation

    10-Q - STRYKER CORP (0000310764) (Filer)

    10/31/25 10:39:02 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Group President Pierce James Andrew gifted 211 shares and received a gift of 211 shares, decreasing direct ownership by 0.32% to 65,630 units (SEC Form 4)

    4 - STRYKER CORP (0000310764) (Issuer)

    11/24/25 4:21:01 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    VP, Chief Financial Officer Wells Preston Wendell sold $60,370 worth of shares (165 units at $365.88), decreasing direct ownership by 2% to 6,694 units (SEC Form 4)

    4 - STRYKER CORP (0000310764) (Issuer)

    11/20/25 4:22:06 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    VP, Chief Accounting Officer Berry William E Jr exercised 4,925 shares at a strike of $154.14, covered exercise/tax liability with 2,972 shares and sold $713,802 worth of shares (1,953 units at $365.49) (SEC Form 4)

    4 - STRYKER CORP (0000310764) (Issuer)

    11/17/25 4:21:07 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stryker declares an $0.88 per share quarterly dividend

    Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter.  "We remain confident in our ability to deliver strong financial performance, and consistent with our capital allocation priorities we are increasing our dividend to $0.88 per share," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are drive

    12/11/25 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker names Spencer Stiles President and Chief Operating Officer

    Portage, Michighan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today Spencer Stiles has been appointed President and Chief Operating Officer (COO), effective January 1, 2026. In this role, Stiles will lead the company's global businesses, strategy, and mergers and acquisitions. "Appointing Spencer President and COO strengthens our ability to sustain high growth and leverage the breadth of our portfolio," said Kevin Lobo, Chair and CEO, Stryker. "Spencer's deep knowledge of our business and our customers, combined with his leadership and operational execution will help position us well for the future." Stiles, a twenty-seven-ye

    12/4/25 8:30:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker reports third quarter 2025 operating results

    Portage, Michigan, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2025: Third Quarter Results Reported net sales increased 10.3% to $6.1 billionOrganic net sales increased 9.5%Reported operating income margin of 18.7%Adjusted operating income margin(1) increased 90 bps to 25.6%Reported EPS increased 2.8% to $2.22Adjusted EPS(1) increased 11.1% to $3.19  Third Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology        14.4        %         0.5        %         13.9        %         5.5        %         8.4        %Orthopaedics        3

    10/30/25 4:05:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rothschild & Co Redburn initiated coverage on Stryker with a new price target

    Rothschild & Co Redburn initiated coverage of Stryker with a rating of Neutral and set a new price target of $420.00

    9/18/25 8:44:39 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Citigroup resumed coverage on Stryker with a new price target

    Citigroup resumed coverage of Stryker with a rating of Buy and set a new price target of $450.00

    2/26/25 7:17:53 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Stryker from Equal-Weight to Overweight and set a new price target of $445.00 from $370.00 previously

    12/2/24 7:02:55 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

    SC 13G/A - STRYKER CORP (0000310764) (Subject)

    2/12/24 10:18:54 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

    SC 13G/A - STRYKER CORP (0000310764) (Subject)

    2/14/23 12:37:55 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

    SC 13G/A - STRYKER CORP (0000310764) (Subject)

    2/10/23 9:18:16 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Financials

    Live finance-specific insights

    View All

    Stryker declares an $0.88 per share quarterly dividend

    Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter.  "We remain confident in our ability to deliver strong financial performance, and consistent with our capital allocation priorities we are increasing our dividend to $0.88 per share," said Kevin Lobo, Chair and Chief Executive Officer, Stryker. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are drive

    12/11/25 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker reports third quarter 2025 operating results

    Portage, Michigan, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2025: Third Quarter Results Reported net sales increased 10.3% to $6.1 billionOrganic net sales increased 9.5%Reported operating income margin of 18.7%Adjusted operating income margin(1) increased 90 bps to 25.6%Reported EPS increased 2.8% to $2.22Adjusted EPS(1) increased 11.1% to $3.19  Third Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology        14.4        %         0.5        %         13.9        %         5.5        %         8.4        %Orthopaedics        3

    10/30/25 4:05:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker declares an $0.84 per share quarterly dividend

    Portage, Michigan, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable October 31, 2025, to shareholders of record at the close of business on September 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more

    8/7/25 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Leadership Updates

    Live Leadership Updates

    View All

    Stryker showcases next generation of Mako SmartRobotics™ at AAOS 2025 Annual Meeting

    Latest technology offers more applications and innovation across more specialties MAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics. With the introduction of Mako Total Hip with Advanced Primary and Rev

    3/11/25 8:03:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Kadant Set to Join S&P SmallCap 600

    NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE:KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE:SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name      Action Company Name Ticker GICS Sector February 19, 2025 S&P SmallCap 600 Addition Kadant KAI Industrials February 19, 2025 S&P SmallCap 600 Deletion Inari Medical NARI Health Care For more information about

    2/13/25 5:54:00 PM ET
    $KAI
    $NARI
    $SPGI
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Stryker announces the retirement of Glenn S. Boehnlein and the promotion of Preston Wells to Vice President, Chief Financial Officer

    Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein's decision follows an impressive 22-year career at Stryker. Preston Wells, who currently serves as Group CFO for Stryker's Orthopaedics Group, will assume the role of Vice President, Chief Financial Officer effective April 1, 2025. "I want to thank Glenn for his performance drive, strong business partnership, and excellent leadership of the Finance and IT organizations. Glenn is a growth champion who invested in developing talent, including Preston Wells, who has been promoted to Chief Financial Offi

    1/28/25 4:05:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care